Theriva Biologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 18.35 million compared to USD 19.69 million a year ago. Basic loss per share from continuing operations was USD 1.14 compared to USD 1.31 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2501 USD | -6.43% | -18.27% | -41.85% |
May. 23 | Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment | MT |
May. 23 | Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.85% | 4.32M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023